Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 27.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 472,028 shares of the company’s stock after purchasing an additional 100,586 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Harmony Biosciences were worth $16,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC raised its holdings in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares in the last quarter. KBC Group NV lifted its position in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after purchasing an additional 819 shares during the last quarter. Quantbot Technologies LP purchased a new position in Harmony Biosciences in the third quarter valued at $74,000. Finally, Avanza Fonder AB acquired a new stake in Harmony Biosciences in the fourth quarter valued at $145,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on HRMY shares. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective on the stock. HC Wainwright reduced their price objective on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Mizuho upped their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, February 25th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences presently has a consensus rating of “Buy” and an average target price of $53.33.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total value of $388,864.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. In the last three months, insiders sold 72,452 shares of company stock worth $2,831,679. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Stock Up 1.5 %

HRMY stock opened at $34.90 on Friday. The stock has a market capitalization of $2.00 billion, a PE ratio of 16.54, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The company has a fifty day moving average of $36.39 and a 200-day moving average of $35.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same quarter in the previous year, the company earned $0.45 EPS. The company’s quarterly revenue was up 19.5% on a year-over-year basis. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.